Gender differences in psychotropic drug metabolism

Psychopharmacology Bulletin

Volumn 33, Issue 2, 1997, Pages 235-241

  Pollock, Bruce G ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Estrogen; Gender; Metabolism; P450; Psychopharmacology

Indexed keywords

PSYCHOTROPIC AGENT;

DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; HEART REPOLARIZATION; HIGH RISK POPULATION; HORMONAL REGULATION; MENSTRUAL CYCLE; PREGNANCY; PRIORITY JOURNAL; PROTEIN BINDING; PSYCHOPHARMACOLOGY; REVIEW; SEX DIFFERENCE;

ANIMALS; ESTROGENS; FEMALE; GASTRIC ACID; HALF-LIFE; HUMANS; MALE; MENSTRUAL CYCLE; METABOLIC CLEARANCE RATE; MICE; PREGNANCY; PROTEIN BINDING; PSYCHOTROPIC DRUGS; RATS; SEX CHARACTERISTICS;

EID: 0030872675     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Abemethy, DR; Greenblatt, DJ; Divoll, M; Arendt, R; Ochs, H; and Shader, RI. Impairment of diazepam metabolism by low-dose estrogen-containing oral contraceptive steroids. N. Engl. J. Med. 306:791-792, 1982.
2. Abernethy, DR; Greenblatt, DJ; and Shader, RI. Imipramine disposition in users of oral contaceptive steroids. Clin. Pharmacol. Ther. 35:792-797, 1984.
3. Akahoshi, M; Soda, M; Nakashima, E; Shimaoka, K; Seto, S; and Yano, K. Effects of menopause on trends of serum cholesterol, blood pressure, and body mass index. Circulation 94:61-66, 1996.
4. Aldridge, A; Bailey, J; and Neims, AH. The disposition of caffeine during and after pregnancy. Sem. Perinatol. 5:310-314, 1981.
5. Aoyama, T; Korzekwa, K; Nagata, K; Gillete, J; Gelboin, HV; and Gonzalez, FJ. Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytocrome P450s. Endocrinology 126:3101-3106, 1990.
6. Baastrup, PC; Christiansen, C; and Transbol, I. Calcium metabolism in lithium treated patients. Acta Psychiatr. Scand. 57:124-128, 1978.
7. Barbhaiya, RH; Buch, AB; and Greene, DS. A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J. Clin. Psychopharmacol. 16:19-25, 1996.
8. Barry, PP. Gender as a factor in treating the elderly. NIDA Res. Monogr. 65:65-69, 1986.
9. Cheng, WSC; Murphy, TL; Smith, MT; Cooksley, WG; Halliday, JW; and Powell, LW. Dose-dependent pharmacokinetics of caffeine in humans: Relevance as a test of quantitative liver function. Clin. Pharmacol. Ther. 47:516-524, 1990.
10. Chernavsky, AC; Valerani, AV; and Burdman, JA. Haloperidol and oestrogens induce c-myc and c-fos expression in the anterior pituitary gland of the rat. Neurol. Res. 15:339-343, 1993.
11. Chouinard, G; Annable, L; and Steinberg, S. A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. J. Clin. Psychopharmacol. 6:21-26, 1986.
12. Cohen, D; Eisdorfer, C; Gorelick, P; Luchins, D; Freels, S; Semla, T; Paveza, G; Shaw, H; and Ashford, JW. Sex differences in the psychiatric manifestations of Alzheimer's disease. J. Am. Geriatr. Soc. 41:229-232, 1993.
13. Dam, M; Christiansen, J; Munck, O; and Mygind, KI. Antiepileptic drugs: Metabolism in pregnancy. Clin. Pharmacokinet. 2:427-436, 1977.
14. Divoll, M; Greenblatt, DJ; Harmatz, JS; and Shader, RI. Effect of age and gender on disposition of temazepam. J. Pharm. Sci. 70:1104-1107, 1981.
15. Domecq, C; Naranjo, CA; Ruiz, I; and Busto, U. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int. J. Clin. Pharmacol. Ther. Toxicol. 18:362-366, 1980.
16. Ereshefsky, L; Saklad, SR; Wantanabe, MD; Davis, CM; and Jann, MW. Thiothixene pharmacokinetic interactions: A study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J. Clin. Psychopharmacol. 11:296-301, 1991.
17. Ford, JM; Truman, CA; Wilcock, GK; and Roberts, CJC. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin. Pharmacol. Ther. 53:691-695, 1993.
18. Frezza, M; di Padova, C; Pozzato, G; Terpin, M; Baraona, E; and Lieber, CS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N. Engl. J. Med. 322:95-99, 1990.
19. Fuhr, U, and Rost, KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 4:109-116, 1994.
20. Gex-Fabry, M; Balant-Gorgia, AE; Balant, LP; and Garrone, G. Clomipramine metabolism: Model-based analysis of variability factors from drug monitoring data. Clin. Pharmacokinet. 19:241-255, 1990.
21. Greenblatt, DJ; Abernethy, DR; and Shader, RI. Pharmacokinetic aspects of drug therapy in the elderly. Ther. Drug Monit. 8:249-255, 1986.
22. Greenblatt, DJ; Allen, MD; Harmatz, JS; and Shader, RI. Diazepam disposition determinants. Clin. Pharmacol. Ther. 27:301-312, 1980.
23. Greenblatt, DJ; Sellers, EM; and Shader, RI. Drug disposition in old age. N. Engl. J. Med. 306:1081-1088, 1982.
24. Greendale, GA, and Judd, HL. The menopause: Health implications and clinical management. J. Am. Geriatr. Soc. 41:426-436, 1993.
25. Guengerich, FP. Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs. Am. J. Obstet. Gynecol. 163:2159-2163, 1990.
26. Gustafsson, J-A; Mode, A; Norstedt, G; and Skett, P. Sex steroid induced changes in hepatic enzymes. Ann. Rev. Physiol. 45:51-60, 1983.
27. Hallonquist, JD; Seeman, MV; Lang, M; and Rector, NA. Variation in symptom severity over the menstrual cycle of schizophrenics. Biol. Psychiatry 33:207-209, 1993.
28. Hammer, W, and Sjöqvist, F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci. 6:1895-1903, 1967.
29. Haring, C; Meise, U; Humpel, C; Saria, A; Fleischhaker, WW; and Hinterhuber, H. Dose-related plasma levels of clozapine: Influence of smoking behavior, sex and age. Psychopharmacology 99:S38-S40, 1989.
30. Harris, RZ; Tsunoda, SM; Mroczkowski, P; Wong, H; and Benet, LZ. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin. Pharmacol. Ther. 59:429-435, 1996.
31. Hartter, S; Wetzel, H; Hammes, E; and Hiemke, C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology 110:302-308, 1993.
32. Hindberg, I, and Naesh, O. Serotonin concentrations in plasma and variations during the menstrual cycle. Clin. Chem. 38:2087-2089, 1992.
33. Homeida, M; Halliwell, M; and Branch, RA. Effects of an oral contraceptive on hepatic size and antipyrine metabolism in premenopausal women. Clin. Pharmacol. Ther. 24:228-232, 1978.
34. Hooper, WD, and Qing, MS. The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans. Clin. Pharmacol. Ther, 48:633-640, 1990.
35. Hurwitz, N. Predisposing factors in adverse reactions to drugs. Br. Med. J. 1:536-539, 1969.
36. Hulst, LK; Fleishaker, JC; Peters, GR; Harry, JD; Wright, DM; and Ward, P. Effect of age and gender on tirilazad pharmacokinetics in humans. Clin. Pharmacol. Ther. 55:378-384, 1994.
37. Hutson, WR; Roehrkasse, RL; and Wald, A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology 96:11-17, 1989.
38. Kato, R, and Yamazoe, Y. Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity. Toxicol. Lett. 64/65:661-667, 1992.
39. Kellermann, GH, and Luyten-Kellermann, M. Antipyrine metabolism in man. Life Sci. 23:2485-2490, 1978.
40. Kimmel, S; Gonsalves, L; Youngs, D; and Gidwani, G. Fluctuating levels of antidepressants premenstrually. J. Psychosom. Obstet. Gynecol. 13:277-280, 1992.
41. Knight, AH, and Rhind, EG. Epilepsy and pregnancy: A study of 153 pregnancies in 59 patients. Epilepsia 16:99-110, 1975.
42. Kristensen, CB. Imipramine serum protein binding in healthy subjects. Clin. Pharmacol. Ther. 34:689-694, 1983.
43. 2 breath tests as monitors of the cytochrome P450 dependent mixed function oxygenase system. In: McLeod, SM; Okey, AB; and Spielberg, SP, eds. Developmental Pharmacology. New York: Alan R Liss, Inc. 1983. pp. 119-145.
44. Luoma, PV. Microsomal enzyme induction, lipoproteins and atherosclerosis. Pharmacol. Toxicol. 62:243-249, 1988.
45. Makkar, RR; Fromm, BS; Steinman, RT; Meissner, MD; and Lehmann, MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270:2590-2597, 1993.
46. May, DG; Porter, J; Wilkinson, GR; and Branch, RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P450 3A4 activity, in a white population. Clin. Pharmacol. Ther. 55:492-500, 1994.
47. Moody, JP; Tait, AC; and Todrick, A. Plasma levels of imipramine and desmethylimipramine during therapy. Br. J. Psychiatry 113:183-193, 1967.
48. Murray, GI; Foster, CO; Barnes, TS; Weaver, RJ; Ewen, SWB; Melvin, WT; and Burke, MD. Expression of cytochrome P4501A in breast cancer. Br. J. Cancer 63:1021-1023, 1991.
49. Nemeroff, CB; De Vane, CL; and Pollock, BG. Newer antidepressants and the cytochrome P450 system. Am. J. Psychiatry 153:311-320, 1996.
50. Nicholas, GS, and Barron, DH. The use of sodium amytal in the production of anesthesia in the rat. J. Pharmacol. Exp. Ther. 46:125-129, 1932.
51. Nordenstrom, J; Strigard, K; Perbeck, L; Willems, J; Bagedahl-Strindlund, M; and Linder, J. Hyperparathyroidism associated with treatment of manic-depressive disorders by lithium. Eur. J. Surg. 158:207-211, 1992.
52. Perucca, E, and Crema, A. Plasma protein binding of drugs in pregnancy. Clin. Pharmacokinet. 7:336-352, 1982.
53. Pollock, BG. Recent developments in drug metabolism of relevance to psychiatrists. Harv. Rev. Psychiatry 2:204-213, 1994.
54. Pollock, BG; Altieri, L; Kirshner, M; Yeager, A; Houck, P; and Reynolds, CF. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol. Bull. 28:163-168, 1992.
55. Rubio, A, and Cox, C. Sex, age and alfentanil pharmacokinetics. Clin. Pharmacokinet. 21:81-82, 1991.
56. Rugstad, HE; Hundal, O; Holme, I; Herland, OB; Husby, G; and Giercksky, KE. Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: Relation to age, sex, efficacy and adverse events. Clin. Rheumatol. 5:389-398, 1986.
57. Schmucker, DL, and Vesell, ES. Underrepresentation of women in clinical drug trials. Clin. Pharmacol. Ther. 54:11-15, 1993.
58. Schneider, LS, and Farlow, MR. Predicting response to cholinesterase inhibitors in Alzheimer's disease. CNS Drugs 4:114-124, 1995.
59. Schneider, LS; Farlow, MR; Henderson, VW; and Pogoda, JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 46:1580-1584, 1996.
60. Schwartz, J; Capili, H; and Daugherty, J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 55:509-517, 1994.
61. Seeman, MV. Interaction of sex, age, and neuroleptic dose. Compr. Psychiatry 24:125-128, 1983.
62. Siegel, B; Shihabuddin, L; and Buchsbaum, M. Gender differences in regional brain glucose utilization in Alzheimer's disease and normal aging (Abstract). Neuropsychopharmacol. 10(Suppl. 3S/Part 2):24, 1994.
63. Simpson, GM; Yadalam, KG; Levinson, DF; Stephanos, MJ; Sing Lo, EE; and Cooper, TB. Single dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. J. Clin. Psychopharmacol. 10:417-421, 1990.
64. Skett, P; Mode, A; Rafter, J; Sahlin, L; and Gustafsson, J-A. The effects of gonadectomy and hypophysectomy on the metabolism of imipramine and lidocaine by the liver of male and female rats. Biochem. Pharmacol. 29:2759-2762, 1980.
65. Stoehr, GP; Kroboth, PD; Juhl, RP; Wender, DB; Philips, JP; and Smith, RB. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin. Pharmacol. Ther. 36: 683-690, 1984.
66. Sweet, RA; Pollock, BG; Wright, B; Kirshner, M; and DeVane, C. Single and multiple dose bupropion pharmacokinetics in elderly patients with depression. J. Clin. Pharmacol. 35:876-884, 1995.
67. Taioli, E; Garte, SJ; Trachman, J; Garbers, S; Sepkovic, DW; Osborne, MP; Mehl, S; and Bradlow, HL. Ethnic differences in estrogen metabolism in healthy women. J. Nat. Cancer Inst. 88:617, 1996.
68. Taioli, E; Trachman, J; Chen, X; Toniolo, P; and Garte, SJ. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res. 55:3757-3758, 1995.
69. Tam, SP. Effects of gemfibrizol and ketoconazole on human apolipoprotein A1, B and E levels in two hepatoma cell lines, HepG2 and Hep3B. Atherosclerosis 91:51-61, 1991.
70. Tamblyn, RM; McLeod, PJ; Abrahamowicz, M; Monette, J; Gayton, DC; Berkson, L; Dauphinee, WD; Grad, RM; Huang, AR; Isaac, LM; Schnarch, BS; and Snell, LS. Questionable prescribing for elderly patients in Quebec. Can. Med. Assoc. J. 150:1801-1809, 1994.
71. Thorogood, M; Cowen, P; Mann, J; Murphy, M; and Vessey, M. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet 340:1067-1068, 1992.
72. ThyagaRajan, S; Meites, J; and Quadri, SK. Underfeeding-induced suppression of mammary tumors: Counteraction by estrogen and haloperidol. Proc. Soc. Exp. Biol. Med. 203:236-242, 1993.
73. Wald, A; Van Thiel, DH; Hoechstetter, L; Gavaler, JS; Egler, KM; Verm, R; Scott, L; and Lester, R. Gastrointestinal transit: The effect of the menstrual cycle. Gastroenterology 80:1497-1500, 1981.
74. Walle, T; Walle, UK; Cowart, TD; and Conradi, EC. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin. Pharmacol. Ther. 46:257-263, 1989.
75. Warren, JL; McBean, AM; Hass, SL; and Babish, JD. Hospitalizations with adverse events caused by digitalis therapy among elderly Medicare beneficiaries. Arch. Intern. Med. 154:1482-1487, 1994.
76. Watkins, PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171-184, 1994.
77. Weinstein, MR. Lithium treatment of women during pregnancy and in the post-delivery period. In: Johnson, FN, ed. Handbook of Lithium Therapy. Baltimore, MD: Baltimore University Park Press, 1980.
78. Wilson, K. Sex-related differences in drug disposition in man. Clin. Pharmacokinet. 9:189-202, 1984.
79. Wilson, K; Oram, M; Horth, CE; and Burnett, D. The influence of the menstrual cycle on the metabolism and clearance of methaqualone. Br. J. Clin. Pharmacol. 14:333-339, 1982.
80. Wisner, KL; Perel, JM; and Wheeler, SB. Tricyclic dose requirements across pregnancy. Am. J. Psychiatry 150:1541-1542, 1993.